Core Viewpoint - Elauwit Connection, Inc. plans to amend and restate its financial statements for the quarter ended September 30, 2025, due to an error in revenue recognition, which does not impact its ongoing business activities or growth plans [1][3]. Financial Restatement - The restatement is a result of an error identified by the internal accounting team regarding network construction project revenue recognition during the first nine months of 2025 [2]. - The error led to an overstatement of revenue, gross profit, operating income (loss), and net loss by approximately $1.4 million for the nine months ended September 30, 2025, and did not occur in periods prior to 2025 [5]. Company Operations and Strategy - Despite the need for restatement, the company asserts that its operations and growth strategy remain unaffected, with a continued focus on expanding its business and onboarding new properties [3][4]. - The company has been successfully winning new customer engagements, which will contribute to its long-term recurring revenue model [3]. Audit Committee Decision - On February 25, 2026, the Audit Committee determined that the company would restate its unaudited condensed consolidated financial statements and amend related disclosures, indicating that previous documents referencing these results should no longer be relied upon [6].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Maravai LifeSciences Holdings, Inc. due to a class action complaint alleging breaches of fiduciary duties by the company's board of directors during a specified class period [2][8]. Group 1: Company Overview - Maravai LifeSciences Holdings, Inc. is facing legal scrutiny following a class action complaint filed on March 3, 2025, concerning events from August 7, 2024, to February 24, 2025 [2]. - The company announced a postponement of its fiscal 2024 earnings release and a delay in filing its annual report due to an error in revenue recognition, which resulted in approximately $3.9 million being incorrectly recorded [8]. Group 2: Financial Impact - Following the announcement of the revenue recognition error, Maravai's share price fell by $0.87, or 21.70%, closing at $3.14 per share on February 25, 2025, amid unusually heavy trading volume [8]. - The class action complaint alleges that the company made materially false and misleading statements regarding its financial health, including inadequate internal controls over financial reporting and overstated goodwill [8]. Group 3: Legal Actions - Investors who purchased Maravai stock during the specified class period are encouraged to contact Bragar Eagel & Squire for discussions regarding their legal rights and options [1][4]. - The law firm emphasizes that there is no cost or obligation for investors to inquire about these claims [4].

Core Viewpoint - Maravai LifeSciences Holdings, Inc. is under investigation for potential claims related to a class action complaint alleging breaches of fiduciary duties by its board of directors during a specified class period [1] Financial Reporting Issues - On February 25, 2025, Maravai announced a postponement of its fiscal 2024 earnings release and the filing of its annual report due to an error in revenue recognition, which resulted in approximately $3.9 million being incorrectly recorded [2] - The company identified a material weakness in its internal controls over revenue recognition and required additional time to assess a potential non-cash impairment charge related to goodwill from its acquisition of Alphazyme LLC [2] Class Action Allegations - The class action complaint alleges that Maravai's executives made materially false and misleading statements and failed to disclose adverse facts about the company's operations and financial reporting [3] - Specific allegations include inadequate internal controls over financial reporting, inaccurate revenue recognition, overstated goodwill, and misleading positive statements about the company's business prospects [3]

Core Viewpoint - A securities fraud lawsuit has been filed against Maravai LifeSciences Holdings, Inc. and certain executives due to issues related to revenue recognition and internal controls [1][3]. Group 1: Company Announcement - On February 25, 2025, Maravai announced a postponement of its fiscal 2024 earnings release and the filing of its annual report on Form 10-K due to an error in revenue recognition, which resulted in approximately $3.9 million being incorrectly recorded [2]. - The company identified a material weakness in its internal controls over revenue recognition and required additional time to assess a potential non-cash impairment charge related to goodwill from its acquisition of Alphazyme LLC [2]. Group 2: Stock Market Reaction - Following the announcement, Maravai's share price fell by $0.87, or 21.70%, closing at $3.14 per share on February 25, 2025, with unusually heavy trading volume [2]. Group 3: Lawsuit Allegations - The lawsuit alleges that Maravai failed to disclose inadequate internal controls over financial reporting related to revenue recognition, leading to inaccurate revenue recognition during fiscal 2024 and an overstated goodwill [3]. - It is claimed that the positive statements made by the defendants regarding the company's business and prospects were materially misleading and lacked a reasonable basis [3]. Group 4: Investor Eligibility - Investors who purchased Maravai common stock between August 7, 2024, and February 24, 2025, and experienced a decline in share value may be eligible to participate in the lawsuit [4]. Group 5: Next Steps for Investors - The deadline for seeking appointment as lead plaintiff is May 5, 2025, and a class has not yet been certified [5]. - Investors are encouraged to contact Block & Leviton for more information regarding their potential claims [5]. Group 6: Whistleblower Information - Individuals with non-public information about Maravai are encouraged to assist in the investigation or file a report with the SEC under the whistleblower program, which may offer rewards of up to 30% of any successful recovery [6]. Group 7: Firm Background - Block & Leviton is recognized as a leading securities class action firm, having recovered billions for defrauded investors and representing many top institutional investors [7].